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Introduction
Despite decreased incidence, gastric cancer (GC) is 
still the fourth most cancer and the second most common 
cause of cancer-related death in the world (Crew et al., 
2006; Ferlay et al., 2010; Brayet et al., 2012). Even with 
the advancement of human cancer therapy, mechanisms 
that have advanced in mammals to protect cells against 
cytotoxic drugs in the environment will continue to 
function as an important obstacle to successful cancer 
treatments (Gottesman, 2002; Kim and Tononock, 2005; 
Nobili et al., 2006). Generally, the multidrug resistance 
(MDR) is characterized by overexpression of ATP-
dependent drug-efflux pumps P-glycoprotein (Pgp), more 
recently known as ABCB1 protein (Gottesman, 2002). The 
ABCB1 protein, a member of the ATP-binding cassette 
(ABC) transporter family, encoded by the ABCB1 gene, 
which considerably influences the distribution of a drug 
across the cell membrane as well as multidrug resistance 
(MDR) of anti-neoplastic drugs (Ueda et al., 1986; Richter 
et al., 2006). 
Compounds of the anthracycline family (doxorubicin, 
daunorubicin, epirubicin), known as substrate for P-gp 
efflux pumps (Perez, 2009) and epirubicin (EPI) belongs to 
ECF regimen treating (epirubicin, cisplatin, fluorouracil) 
(Findlay et al., 1994). Importantly, this treatment regimen 
improved outcomes in patients with the advanced gastric 
cancer (Wagner et al., 2005) and patients undergoing 
surgery following neoadjuvant chemotherapy had a 
statistically improved overall survival (Cunningham et 
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al., 2006). Nevertheless, increased expression of mRNA 
ABCB1 gene as a predictor of poor clinical outcome to 
epirubicin treatment exemplifies the success of studies 
focused on the cellular pharmacology of epirubicin 
resistance (Yuan et al., 2009). 
Strategies for inducing in vitro resistance has been 
little explored and, furthermore, to demonstrate how such 
models of GC cell lines is an important step in the study of 
the role of in vitro chemoresistance assays in the GC field. 
A significant advance was shown recently by Chen et al., 
(2013) that established the TSGH-S3 oxaliplatin-resistant 
cell line from TSGH human gastric adenocarcinoma. 
Similarly, but in other tumors, a study performed by 
Dupuis et al. (2013) reported that vinblastine-resistant 
leukemia cell lines were well-established and isolated by 
stepwise selection of the parental drug sensitive in the 
existence of increasing vinblastine concentrations. Finally, 
Chen et al., (2013) conducted a study that established a 
paclitaxel-resistant breast cancer cell line to explore the 
mechanisms of MDR in breast cancer. 
To dissect the mechanisms underlying epirubicin 
resistance, we established an epirubicin-resistant cell 
subline (AGS/EPI), from human gastric adenocarcinoma 
AGS cells. In the work reported here, we evaluated the 
chemoresistance differences between the AGS/EPI cell 
subline and AGS cells. Furthermore, we assessed the 
expression profile of mRNA of the ABCB1 gene between 
cell lines, suggesting that their overexpression may also 
contribute to MDR development. The purpose of this study 
was to establish an epirubicin-resistant cell subline (AGS/
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EPI) from human gastric adenocarcinoma AGS cells, and 
to further elucidate the mechanisms involved in acquired 
epirubicin resistance of gastric cancers.
Materials and Methods
Chemicals and media
Epirubicin Hydrochloride solution was purchased from 
Accord Healthcare Ltd, (Middlesex, Wielka Brytania, 
UK). All reagents and cell culture media were from 
Invitrogen/ Life Technologies or Gibco/Life Technologies 
(Carlsbad, CA, USA). All other chemical reagents were 
from either Ambion, Molecular Probes/Life Technologies 
(Carlsbad, CA, USA) or Qiagen (Valencia, CA, USA). 
Cell culture and development of the in vitro chemoresistant 
cell subline
Human gastric adenocarcinoma cell line AGS (Rio de 
Janeiro Cell Bank, BCRJ, ID 0311, Brazil) was cultured 
in RPMI, supplemented with 2 mM L-glutamine, 100 
units/mL penicillin, 100 μg/mL streptomycin, and 10% 
fetal bovine serum at 37°C in a humidified incubator with 
5% CO2. The AGS/EPI cell subline was developed by 
exposing the parental AGS cells to stepwise increasing 
concentrations of anticancer drug EPI [up to the final 
concentration of 0.125uM and 1uM, respectively]. Both 
cell lines were cultured under the same conditions but 
with drug-free medium for 10 days before commencing 
the experiment.
Cytotoxicity assay
T h e  i n  v i t ro  c y t o t o x i c i t y  a s s a y s  w e r e 
performed by 2-(4,5-dimethyltriazol-2yl)-2,5-
diphenyltetrazoliumbromide (MTT) colormetric assay 
(Mosmann, 1983; Hussain et al., 1993). Approximately 
1x104 cells/well AGS/EPI cells subline or AGS cells were 
washed with PBS and seeded in 96-well U-bottom culture 
plates for 24hr at 37°C in a 5 % CO2 humid atmosphere 
incubator. After incubation, cells were exposed to various 
concentrations of EPI. Following overnight incubation, the 
medium was removed and cells then cells were incubated 
in 100 μl of RPMI containing 5 mg/mL MTT for a further 
4 hr. To develop the color 100μL of acid-isopropanol 
(0.04 M HCL in isopropanol) were added to dissolve the 
formazan crystals. The absorbance was measured on a 
microplate reader Elx800™ (BIO-TEK Instruments, Inc., 
Winooski, VT, USA) at a wavelength of 570 nm, with a 
reference wavelength of 630 nm, against medium only 
blank. Cytotoxicity was determined as the ratio between 
the absorbance measured for EPI treated cell samples and 
the absorption measured for untreated cell samples. The 
half maximal inhibitory concentration (IC) was based 
on the growth inhibition rate attained. EPI-resistance 
folds=IC (EPI-resistant cells)/IC (EPI-sensitive cells).
Quantitative real-time reverse transcription PCR (qRT-
PCR)
Reverse-transcriptase reactions were performed 
using the TaqMan Gene Expression Cell-to-CT kit™ 
(Ambion) following the manufacturer’s protocol. cDNA 
specific to ABCB1 mRNA was amplified with TaqMan 
Gene Expression Assays were purchased for human 
ABCB1 (TaqMan Gene Expression Assays™) Inventoried 
Analysis Identification Number (ID): Hs00184491_m1, 
and Endogenous control human β-actin (ACTB) Assay, 
Inventoried assay ID: Hs01060665_g1 from Applied 
Biosystems (ABI, Foster City, CA). In each experiment, 
triplicate reactions were performed in each sample. 
Reactions were incubated in a 96-well plate at 95°C for 10 
min, followed by 40 cycles of 95°C for 15 s and 60°C for 
1 min. using the Step One Plus™ Real-Time PCR System 
(Applied Biosystems, Carlsbad, CA, USA). The relative 
quantity of mRNA for each sample were calculated by 
2-ΔΔCT, where ΔCT=(mean of triplicate CTABCB1-mean of 
triplicate CTACTB) and ΔΔCT=(ΔCT-mean ΔCT of all 
the samples). In pilot studies, the PCR amplicons were 
evaluated on agarose gels to verify product size. 
DNA fragmentation
Apoptosis was analyzed by DNA fragmentation was 
examined by agarose gel electrophoresis as described 
previous (Lee and Bahaman, 2012; Simsek and Uysal, 
2013). Briefly, 2×106 cell/mL AGS/EPI cells subline 
and AGS cells were grown in 25cm2 flasks and treated 
with EPI at IC50 dose and incubated for 48 h. Control 
plates were also made with 0.05% DMSO at a similar 
period of time. Then cells were harvested and collected 
by centrifugation. DNA was extracted and isolated from 
control and treated cells using the QIAamp ™ DNA 
Mini Kit (Qiagen, Valencia, CA, USA) according to 
the manufacturer’s instructions. Three micrograms of 
DNA were stained with ethidium bromide and subjected 
to electrophoresis at 70 V for 1 h in 1.2% agarose gel. 
Separated DNA fragments were visualized under UVP 
ultraviolet light transilluminator /Cannon camera system 
(UVP Laboratory Products, Upland, CA, USA). 
Cell viability assay 
The viable cells counts were obtained by trypan blue 
exclusion method. Treated [with EPI at IC50 by 48 h] and 
untreated AGS/EPI cells subline and AGS cells were 
grown to confluence and trypsinized with 0.05% Trypsin-
EDTA for 5 minutes, centrifuged at 800 rpm for 2 minutes. 
Fifteen microlitres of cell suspension was gently mixed 
with 15µL of 0.4 % trypan blue solution (Invitrogen, 
Carlsbad, CA, USA), and incubated for 5 min at room 
temperature. Ten microlitres of the stained cell suspension 
was placed in a Countess™ cell counting chamber slides 
and the number of viable was measured by trypan blue 
exclusion assay on a Countess™ automated cell counter 
(Applied Biosystems, Carlsbad, CA, USA).
Statistical analysis
All experiments were performed at least in triplicate. 
Statistical calculations were performed using Minitab 
V16.0 software (State College, PA). The data of continuous 
variables were expressed as mean ± standard deviation 
(SD). Pearson’s correlation analysis was used to determine 
the relationship between mRNA expressions and the 
resistance to EPI. All other statistical differences were 
determinate with unpaired two-tailed t-test. Differences 
were considered significant for p <0.05.
Asian Pacific Journal of Cancer Prevention, Vol 15, 2014 6851
DOI:http://dx.doi.org/10.7314/APJCP.2014.15.16.6849
Establishment of a Gastric Cancer Epirubicin-Resistant Cell Line Featuring Upregulation of ABCB1
Results 
Cytotoxicity effect of epirubicin on AGS/EPI cell subline
The human AGS and AGS/EPI gastric cancer cell 
subline were verified by MTT assay to evaluate the effect 
of EPI on cell survival. Drug cytotoxicity in AGS/EPI 
cell subline and AGS cell line by comparing between cell 
viability, as indicated in Figure 1A. Epirubicin was able 
to inhibit differently in these two cell lines. In both cell 
lines were shown not to be similarly susceptible to EPI 
when contrasted with the inhibitory concentrations (IC) 
10, 50 and 90% of cell survival. Comparisons between 
the fold-change results found by inhibitory concentration 
(IC) for AGS/EPI cell subline and AGS cell line were 
investigated. The chemoresistance to EPI increased up 
to 6-fold for AGS/EPI cell subline versus AGS cell line 
(p<0.05) corresponding to IC10; 2.52-fold greater to IC50 
(p<0.05); and 2.39-fold increased to EPI for IC90 (p<0.05), 
respectively, as showed in Figure 1B. The AGS/EPI cells 
subline were found to be resistant to a high concentration 
of EPI, but AGS cells were EPI sensitive. 
Relationship between mRNA expressions and resistance 
to EPI 
The quantitative real-time reverse transcription PCR 
(qRT-PCR) was performed to measure ABCB1 mRNA 
expression as illustrated in Figure 2A. Expression levels 
of ABCB1 mRNA in AGS/EPI cell subline and AGS cell 
line were quantified and we investigated the relationship 
between their expression and chemoresistance to EPI 
(IC50). A statistically significant direct correlation between 
ABCB1 mRNA expression and chemoresistance to EPI 
(IC50) (R2=0.987, p=0.001) as is demonstrated in Figure 
2B.
Relationship between DNA fragmentation and cell 
viability assay
The DNA fragmentation assays were carried out to 
measure apoptosis coincided with the cells deaths results 
analyzed by trypan blue exclusion assay. From the figure 
3A indicates that the EPI therapy showed lower decreasing 
of DNA fragmentation in AGS/EPI cell subline when 
contrasted with AGS cell line, as proof by the development 
of 180-200bp ladder DNA in 1.2% agarose gel. AGS/
EPI and AGS cells deaths were analyzed by Countess™. 
Automated Cell Counter (Invitrogen). Treated cells 
survival was statistically higher (approximately 30%) in 
AGS/EPI cell subline than in AGS cell line (85% versus 
57%, p<0.05) after Trypan Blue staining, as showed in 
Figure 3B.
Discussion
An increasing number of studies on the ABCB1/P-
glycoprotein effects have been explored in the last years 
(Chen et al., 2013; Yang et al., 2013; Zhu et al., 2013; 
Figure 1. Epirubicin (EPI) Cytotoxicity Effects on the 
cell Viability of AGS and AGS/EPI gastric Cancer Cell 
Lines. (A) It was verified that for EPI there was a significant 
differences between the viability of the AGS and AGS/EPI 
gastric cancer cell for all EPI concentrations. Each graph point 
represents the mean values based on five or six replicates of 
the experiment. The error bars indicates the standard deviation 
of the measurements. Unpaired t-test shows statistically 
significant differences (p<0.05). (B) Chemoresistance of EPI 
inhibitory concentrations (IC) of AGS-EPI and AGS cell lines. 
Significant statistical differences were observed between IC10 
of the AGS/EPI and AGS cell line (2.41 µg/mL±1.22 and 0.38 
µg/mL±0.56, p<0.05*); IC50 (8.27 µg/mL±1.22 and 3.24 µg/
mL±0.56, p<0.05*); and IC90 (17.33±1.22 and 7.26±0.56, 
p<0.05*), for IC10. All data shown are averages±SEM of three 
biological replicates
Figure 2. ABCB1 mRNA Expression Levels in AGS/
EPI and AGS Gastric Cancer Cell Lines. (A) The 2−ΔΔCt 
equation results value to the AGS/EPI cell line was 1.923-fold 
higher than that of the AGS cell line as mean±SE (7.050±0.07 
vs 7.994±0.017, *p<0.05). (B) Correlation between mRNA 
expression of ABCB1 levels in AGS/EPI and AGS gastric cancer 
cell lines by chemoresistance to EPI (IC50). Pearson’s correlation 
analysis traces a regression line showing the relation between 
both devices. ABCB1 mRNA expression was significantly 
correlated with chemoresistance to EPI
Figure 3. AGS/EPI and AGS Cells Were Treated with 
Epirubicin (EPI) by IC50 value [3.24 µg/mL] for 48 
Hours. Control experiments without EPI treatment were 
performed using AGS cells. (A) DNA fragmentation assay 
where a concentration around 1 μg/μL (13 μL) of DNA was 
electrophoresed into each well and performed at 70 V for 60 
min using 1.2% agarose gel along with the 250 bp ladder DNA 
size markers. (B) Cell viability was measured with following 
0.4% trypan blue staining and Countess™ automated cell counter 
analysis. The cell viability was normalized as 100% in the control 
group before estimating the viability cell percentage. Data are 
reported as mean±S.D. of experiments performed in triplicate. 
*p<0.05. p values were determined using a two-tailed t-test
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Louisa et al., 2014). The MDR occasioned by increased 
efflux transporters, including ATP-binding cassette 
transporters is associated with upregulated ABCB1 
expression and main cause of treatment failure (Ueda et 
al., 1986; Gottesman, et al., 2002; Richter et al., 2006), and 
can be observed in the majority of cancers (Cordon-Cardo 
et al., 1990). In previous studies conducted by our group 
(Oliveira et al., 2012), we described a case-control study 
of C3435T ABCB1 gene polymorphism that showed that 
there was no association between its polymorphism and 
susceptibility to gastric cancer (GC). 
In the present study, we report on the possibility of 
establishing a GC epirubicin-resistant cell line. Most 
commonly, researchers have used primary cell culture 
studies to evaluation of intrinsic chemoresistance status 
in GC cells (Ying et al., 2013). We can elucidate this 
phenomenon in the opposite way as in the previous works, 
through the development of the in vitro chemoresistant cell 
model and then determine the phenotypic characteristics 
of cells acquired resistance to EPI. 
According cytotoxicity data for treated cell lines, we 
have verified that the AGS/EPI cells subline were resistant 
to a high concentration of EPI, but AGS cells were EPI 
sensitive. In this study, the cytotoxicity of EPI has been 
shown lower for AGS/EPI cells subline than for AGS cells. 
Thus, we searched a correlation between our measure of 
EPI inhibitory concentrations (IC) on AGS cell line [3.24 
µg/mL] and the value found by others researchers on the 
SGC7901 gastric cancer cell line [1.9 µg/mL] (Zhao et al., 
2009). It was verified that there was a slight association 
between the cytotoxicities of the AGS and SGC7901 
gastric cancer cell lines to IC50 values of EPI.
The important role of ABCB1 transporter protein in 
specific tissues is an effective mechanism for detoxifying 
normal cells, however, as well as increased anticancer 
activity during chemotherapy has been widely reported. 
Although, its pharmacological benefit remains unclear 
(Gottesman, 2002). As mentioned above, we reported 
that the mRNA expression of ABCB1 in AGS/EPI 
cell subline was shown to be expressed at 1.943-fold 
higher levels when exposed to stepwise increasing EPI 
concentrations under growth conditions, than the AGS 
cells. Furthermore, when we compared the fold-change 
results found by inhibitory concentration and expression 
levels of mRNA of ABCB1 in AGS/EPI cell subline, 
these results showed a statistically significant positive 
correlation between ABCB1 mRNA expression and EPI 
resistance. This decreased cytotoxity against the AGS/
EPI cell subline was smaller than expected, seeing that 
the others authors (Chen et al., 2013; Chen et al., 2013; 
Dupuis et al., 2013) established the highest fold change 
to chemoresistance in parallel investigations in their own 
laboratories. Furthermore, our data suggest that AGS/
EPI cell subline can be used to investigate the effects of 
the reversal modulators to chemoresistance, as a study 
performed by Louisa et al., (2014) concluded that the 
mangiferin modulators effects were related to a reduction 
of the ABCB1/P-glycoprotein expressions. Our data and 
that of others (Redmond et al., 2008; Gillet et al., 2011) 
suggest that the levels of mRNA transcripts encoding 
ABCB1 protein may be increased in the presence of 
EPI. Thus, intracellular EPI depletion resulted in post-
transcriptional upregulation of ABCB1 protein on AGS 
surface expression. 
DNA laddering assay demonstrated a nucleosomal 
fragmentation, which is a well documented as hallmarks 
of apoptosis. The evolution of in vitro chemotherapy 
resistance in a variety of cancer cells has been associated 
with a decreased susceptibility to drug-induced apoptosis 
(Plati et al., 2008). From these experiments it was 
determined that EPI treatment-induced showed low-
decreasing of DNA chromosomal degradation in AGS/
EPI cell subline when compared with AGS cell line. 
Likewise, the results of both analyses indicated that there 
was an increased level of apoptosis in AGS cell lines when 
compared with AGS/EPI cell subline.
In order to confirm all assays that established a GC 
epirubicin-resistant AGS/EPI cell subline, we performed 
several analyses to ensure that analytical results were 
acceptably reproducible. Based on these observations, 
we conclude that AGS/EPI cell line was successfully 
established in our laboratory, and which can be effectively 
applied to understanding of the MDR reversal mechanisms 
in future studies. Additionally, ABCB1 overexpression 
emerged as an important pharmacological risk factor 
for treatment failure of gastric cancer AGS cell line 
epirubicin-resistant.
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